Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 2a Study to Evaluate Pazopanib Eye Drops Administered for 12 Weeks to Patients With Neovascular Age-related Macular Degeneration

NCT01362348 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01362348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01362348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 2a Study to Evaluate Pazopanib Eye Drops Administered for 12 Weeks to Patients With Neovascular Age-related Macular Degeneration
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
July 7, 2011
Completion date
April 16, 2012
Enrollment
19 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration